Januvia and Victoza Pancreatic Cancer Lawsuits Have Begun

The lawyers are circling  all drug makers of incretin mimetics, including the newer DPP-4 inhibitors – Tradjenta (linagliptin) from Eli Lilly (LLY-$49.89) and Nesina (alogliptin) from Takeda – as a growing body of evidence suggests causality between use and increased risk of pancreatic injury. In addition to lost sales, the drug makers will need to put aside reserves due to the possibility of multi-million dollar injury settlements.

See more at YCharts: Diabetic Franchises at Risk

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.